GRM1 and epilepsy: The selective mGluR1 antagonist, LY456236, exerts dose-related anticonvulsant effects for limbic seizures in the 6-Hz focal seizure model and the inhibition of tonic extensor seizures in the threshold electroshock model, suggesting that a mGluR1 blockade may be a clinically useful approach to treating epilepsy [19].